CTSO Earnings Prediction
The chart below shows how CTSO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CTSO sees a +8.01% change in stock price 10 days leading up to the earnings, and a -0.13% change 10 days following the report. On the earnings day itself, the stock moves by -3.77%. This data can give you a slight idea of what to expect for the next quarter's release.
CTSO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
9.39M
6.58%
-5.10%
Gross Margin
56.24%
-11.63%
-14.42%
Operating Margin
-46.13%
-43.29%
41.16%
Net Margin
-24.86%
-76.17%
-40.63%
EPS
-0.04
-80.95%
-50.00%
No Data Available
CTSO Earnings Analysis
Cytosorbents Corp. Corporation (CTSO.O) Earnings Conference Call
Positive
Product Sales Increase: 1. Product Sales Growth: Q3 2024 product sales reached $8.6 million, exceeding guidance and reflecting an 11% year-over-year increase.
Operating Expense Reduction: 2. Improved Operating Efficiency: Operating expenses decreased by 25% year-over-year, leading to a 40% reduction in operating loss compared to the previous year.
Cash Burn Reduction: 3. Strong Cash Management: Cash burn for the quarter was reduced to approximately $2.7 million, down from $5 million in the second quarter, demonstrating effective cost management.
Regulatory Approval Progress: 4. Regulatory Milestones Achieved: The company received MDSAP certification and submitted its medical device license application to Health Canada, marking significant progress in regulatory approvals.
Clinical Trial Success: 5. Positive Clinical Trial Results: The STAR-T trial showed that DrugSorb ATR significantly reduced severe bleeding in CABG patients, with a number needed to treat of just 6 to prevent a major bleed.
Negative
Grant Revenue Decline: 1. Declining Grant Revenue: Grant revenue decreased to approximately $800,000 in Q3 2024 from $1.1 million in the prior year, reflecting the conclusion of several grants over the past 12 months.
Declining Gross Margins: 2. Lower Product Gross Margins: Product gross margins fell to 61% in Q3 2024, down from 72% in the prior year's quarter, due to a planned production slowdown and a short-term manufacturing issue.
Operating Loss Improvement: 3. Operating Loss: Despite a 40% improvement year-over-year, the operating loss remains significant at $2.3 million for Q3 2024, compared to a net loss of $9.2 million in the prior year.
Liquidity Challenges Ahead: 4. Cash Position Concerns: As of September 30, 2024, the company had $12.2 million in cash, which includes $6.5 million of restricted cash, raising concerns about liquidity as they prepare for the DrugSorb ATR launch.
Production Slowdown Effects: 5. Production Slowdown Impact: The planned slowdown in production to rebalance inventory levels resulted in a significantly lower number of CytoSorb devices produced during the quarter, affecting overall sales performance.
CTSO FAQs
How does CTSO typically perform around its earnings report dates?
Is Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CTSO Earning Call Sentiment
Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CTSO.O
2.73%Positive
The earnings call summary indicates positive financial performance with revenue growth and operating loss reduction. The Q&A section suggests positive sentiment towards regulatory progress and product launches. Despite competitive pressures and cash flow management concerns, the company's strategic initiatives and cost-cutting measures seem promising. The lack of specific FDA approval timelines may introduce some uncertainty, but overall, the sentiment leans positive with expectations of future growth and improved margins.
